TrabectedinA Review of its Use in Soft Tissue Sarcoma and Ovarian Cancer

被引：61

作者：

Natalie J. Carter

Susan J. Keam

机构：

[1] Adis,

[2] a Wolters Kluwer Business,undefined

来源：

Drugs | 2010年 / 70卷 / 3期

关键词：

Soft Tissue Sarcoma; Liposarcoma; Liposomal Doxorubicin; Trabectedin; Recurrent Ovarian Cancer;

D O I：

10.2165/11202860-000000000-00000

中图分类号：

学科分类号：

摘要：

Trabectedin (Yondelis®) is a tetrahydroisoquinoline molecule that was originally derived from a marine organism. It is indicated in the EU and many other countries for use in patients with advanced soft-tissue sarcoma (STS) who have progressed despite receiving previous treatment with anthracyclines and ifosfa-mide or in those who are unable to receive these agents. It is also approved in the EU in combination with pegylated liposomal doxorubicin for the treatment of platinum-sensitive, recurrent ovarian cancer. In addition, trabectedin holds orphan drug status for the treatment of advanced, recurrent STS in the US, Switzerland and Korea, and for the treatment of advanced, recurrent ovarian cancer in the US and Switzerland.

引用

页码：355 / 376

页数：21

共 235 条

[1]

Schöffski P(2008)Clinical impact of trabectedin (ecteinascidin-743) in advanced/metastatic soft tissue sarcoma Expert Opin Pharmacother 9 1609-18

[2]

Dumez H(2008)Soft tissue sarcomas: ESMO clinical recommendations for diagnosis, treatment and follow-up Ann Oncol 19 ii89-93

[3]

Wolter P(2005)Recent developments in salvage chemotherapy for patients with metastatic soft tissue sarcoma Drugs 65 167-78

[4]

Casali PG(2005)Soft-tissue sarcomas in adults N Engl J Med 353 701-11

[5]

Jost L(2006)ET-743: a novel agent with activity in soft-tissue sarcomas Curr Opin Oncol 18 347-53

[6]

Sleijfer S(2007)Trabectedin: a review of its use in the management of soft tissue sarcoma and ovarian cancer Drugs 67 2257-76

[7]

Hartmann JT(2008)Marine metabolites overcoming or circumventing multidrug resistance mediated by ATP-dependent transporters: a new hope for patient with tumors resistant to conventional chemotherapy Anticancer Agents Med Chem 8 886-903

[8]

Patel S(2002)ET-743 [published erratum appears in Drugs 2002; 62(11): 1634] Drugs 62 1185-92

[9]

Clark MA(2009)Development of Yondelis® (trabectedin, ET-743): asemisynthetic process solves the supply problem Nat Prod Rep 26 322-37

[10]

Fisher C(2003) interaction between ecteinascidin 743 (ET-743) and radiation, in relation to its cell cycle effects Br J Cancer 89 2305-11

← 1 2 3 4 5 6 7 8 9 10 →